# Nonthermal biocompatible plasma in stimulating osteogenic differentiation by targeting p38/ FOXO1 and PI3K/AKT pathways in hBMSCs

**Authors:** Khadija Akter, Youngsun Kim, Eun Ha Choi, Ihn Han

PMC · DOI: 10.1186/s13036-024-00419-2 · 2024-05-28

## TL;DR

Nonthermal plasma boosts bone cell development in human stem cells by activating specific signaling pathways, offering potential for treating osteoporosis.

## Contribution

This study reveals how nonthermal plasma promotes bone cell differentiation via p38/FOXO1 and PI3K/AKT pathways in hBMSCs.

## Key findings

- Nonthermal plasma enhances osteogenic differentiation in hBMSCs.
- NBP activates the p38/FOXO1 pathway and the PI3K/AKT signaling cascade.
- BMP signaling is upregulated, contributing to bone cell development.

## Abstract

Osteoporosis is manifested by decreased bone density and deterioration of bone architecture, increasing the risk of bone fractures Human bone marrow mesenchymal stem cells (hBMSCs)-based tissue engineering serves as a crucial technique for regenerating lost bone and preventing osteoporosis. Non-thermal biocompatible plasma (NBP) is a potential new therapeutic approach employed in several biomedical applications, including regenerative medicine. NBP affects bone remodeling; however, its role in the regulation of osteogenic differentiation in hBMSCs remains largely unexplored. This study aimed to explore the efficiency of NBP in promoting osteogenic differentiation, and the molecular pathways through which these responses occurred in hBMSCs. We found that NBP facilitated osteogenic differentiation through the upregulation of the bone morphogenic protein signal (BMPs) cascade, which in turn induced the expression of p38 and inhibited the forkhead box protein O1 (FOXO1). To further gain insight into the mechanism through which NBP extensively triggers the initiation of osteogenic differentiation in hBMSCs, PI3K/AKT pathway was also analyzed. Overall, these results highlight that NBP enhances osteogenic differentiation in hBMSCs by the stimulation of the p38/FOXO1 through PI3K/AKT signaling pathways. Therefore, the application of NBP in hBMSCs may offer tremendous therapeutic prospects in the treatment of bone regeneration and osteoporosis prevention.

The online version contains supplementary material available at 10.1186/s13036-024-00419-2.

## Linked entities

- **Genes:** CRK (CRK proto-oncogene, adaptor protein) [NCBI Gene 1398], FOXO1 (forkhead box O1) [NCBI Gene 2308], PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) [NCBI Gene 5290], AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207]
- **Diseases:** osteoporosis (MONDO:0005298)

## Full-text entities

- **Genes:** MAPK14 (mitogen-activated protein kinase 14) [NCBI Gene 1432] {aka CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, FOXO1 (forkhead box O1) [NCBI Gene 2308] {aka FKH1, FKHR, FOXO1A}
- **Diseases:** bone fractures (MESH:D050723), Osteoporosis (MESH:D010024)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11134625/full.md

---
Source: https://tomesphere.com/paper/PMC11134625